Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.
BACKGROUND
To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment.


METHODS
Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months.


RESULTS
All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection. Best-corrected visual acuity (BCVA) decreased in the three cases more than 20 letters due to early foveal involvement.


CONCLUSIONS
Two different foci of CNV show a great tendency to decrease patients' vision because of neovascular bridging with foveal implication.
Reche-Frutos
Juan
J
Hospital Clínico Universitario San Carlos, Calle Profesor Martín Lagos s/n, Madrid, Spain. echejuan@yahoo.es
Calvo-Gonzalez
Cristina
C
Donate-Lopez
Juan
J
Garcia-Feijoo
Julian
J
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002833:Choroiditis / Q000150:complications*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis / Q000473:pathology; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D047728:Myopia, Degenerative / Q000150:complications*; D009887:Ophthalmoscopy; D000069579:Ranibizumab; D014792:Visual Acuity / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab